Odne secures investment from Dental Innovation Alliance (DIA) to accelerate US launch of FDA-approved dental health solutions

23.01.2024 09:30, Rita Longobardi

Odne's innovative root preservation therapy, designed to minimize the use of bleach and enhance treatment speed in endodontic therapy, prioritizes patient safety and comfort while preserving tooth structures for optimal long-term outcomes. The funding from DIA not only recognizes Odne's innovative solutions but also serves as a strategic move to facilitate the company's US launch, further advancing the future of dental healthcare.

DIA recognizes the significance of Odne's commitment to advancing dental technology while prioritizing patient well-being. The reduction of bleach and fast workflows aligns with DIA's dedication to scaling technologies that promote safer and more efficient practices within the dental industry. Several Dental Support Organizations (DSOs) affiliated with DIA are poised to be early adopters of Odne's latest product which has FDA approval and is set to launch in Q2 2024.

DIA anticipates the positive impact that the partnership with Odne (former Lumendo) will have on its mission of accelerating dental technology innovations for the betterment of all stakeholders.

Odne was ranked among the TOP 100 Swiss Startups in 2022, won the last stage of Venture Kick in 2017, and participated in Venture Leaders Life Sciences in 2017. "With Venture Leaders we were able to meet top KOLs, partners and future VCs for our startup!" commented Andreas Schmocker, CEO and Co-founder of Odne.


Odne's team from up left to down right: Mark Bispinghoff (COO & Co-Founder), Barbara Hochstrasser (Quality Manager), Philipp Stücklin (CTO), Silviu Boanta (Development Engineer), Holger Essig (General Manager Europe & Global Marketing), Andreas Schneider (Product Manager), Andreas Schmocker (CEO & Co-Founder), Barbara Kunz (Head Administration), and Else Ellermann (Scientific Affairs Associate)